2,4-DIFLUORO-2-METHIL NUCLEOSIDE DERIVATIVES REPLACED AS HCV-RNA REPLICATION INHIBITORS

专利摘要:
NUCLEOSIDE 2, 4-DIFLUORO-2-METHY DERIVATIVES REPLACED AS HCV-RNA REPLICATION INHIBITORS The present description refers to the compounds of Formula I: Also exposed are the pharmaceutical compositions comprising the compounds of Formula I, the methods of use of Formula I compounds and / or compositions comprising Formula I compounds for the treatment of HCV.
公开号:BR112014013661B1
申请号:R112014013661-0
申请日:2012-12-17
公开日:2020-10-27
发明作者:Jing Zhang；Zhuming Zhang
申请人:Riboscience Llc.；
IPC主号:

专利说明:

Field of the Invention
[0001] The invention relates to nucleoside derivatives as inhibitors of HCV replication RNA replication. In particular, the invention relates to the use of nucleoside derivatives of purine and pyrimidine as replication inhibitors of Hepatitis comprised of C Virus (HCV) subgenomic RNA and pharmaceutical compositions containing such compounds.
[0002] The hepatitis C virus is the leading cause of chronic liver disease worldwide. HCV-infected patients are at risk of developing liver cirrhosis and subsequent hepatocellular carcinoma and thus HCV is the main indication for liver transplantation. Only two approved therapies are currently available for the treatment of HCV infection (R. G. Gish. Sem. Liver. Dis., 1999, 19, 35). They are the monotherapy of interferon-oc and, more recently, the combination therapy of the nucleoside analog, ribavirin (Virazole), with interferon-oc.
[0003] Many of the drugs approved for the treatment of oral infections are nucleosides or nucleoside analogues and most of these nucleoside analog drugs inhibit virus replication, following the conversion of the corresponding triphosphates by inhibiting the viral polymerase enzymes. This conversion to triphosphate is commonly mediated by cell kinases and for that reason the direct evaluation of nucleosides as inhibitors of HCV replication is only conveniently performed using a cell-based assay. HCV lacks the availability of a true cell-based viral replication assay or animal infection model.
[0004] The Hepatitis C virus belongs to the family of Flaviridae. It is an RNA virus, the genome of the RNA that encodes a broad polyprotein that after processing produces the necessary replication mechanism to ensure the synthesis of progeny RNA. Most of the non-structural proteins encoded by the HCV RNA genome are believed to be involved in RNA replication. Lohmann et al. [V. Lohmann et al., Science, 1999, 285, 110-113] described the construction of a Human Hepatoma (Huh7) cell line in which subgenomic HCV RNA molecules were introduced and shown to replicate with high efficiency. The mechanism of RNA replication in these cell lines is believed to be identical to replication of the full length of the HCV RNA genome in infected hepatocytes. The subgenomic HCV cDNA clones used for the isolation of these cell lines formed the basis for the development of a cell-based assay to identify nucleoside analog HCV replication inhibitors. Summary of the Invention
[0005] The compounds of Formula I are useful for the treatment of diseases mediated by the Hepatitis C Virus (HCV) and for the pharmaceutical compositions comprising these compounds.
[0006] The application provides a compound of Formula I
where: R1 is H, lower haloalkyl, or aryl, where aryl is phenyl or naphthyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, halo, lower haloalkyl, - N (Rla) 2 , acylamino, -SO2N (Rla) 2, -CORlb, -S02 (Rlc), -NHSO2 (Rlc), nitro or cyano; each Rla is independently H or lower alkyl; each Rlb is independently -0Rla or -N (Rla) 2; each Rlc is lower alkyl; R2a and Rab are (1) independently H, lower alkyl, - (CH2) rN (Rla) 2, lower hydroxyalkyl, -CH2SH, (CH2) S (0) PMe, - (CH2) 3NHC (= NH) NH2, ( 1H-indol-3-yl) methyl, (1H-indol-4-yl) methyl, - (CH2) mC (= 0) Rlb, aryl and aryl lower alkyl, where aryl can be optionally substituted with one or more of hydroxyl, lower alkyl, lower alkoxy, halo, nitro or cyano; (11) R "a is H and R ~ b and R4 together form (CH2) 3; (fir) R and R together form (CH2) n; or, (iv) R2a and R2b both are lower alkyl; - RJ is H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl; R4 is H, lower alkyl, or R2b and R4 together form (CH2) 3; R5 is H, C (= O) Rlc, C (= O ) Rlb, P (= 0) (OR1) (0Rla), or P (= 0) (OR1) (NR4R7); R6 is H, methyl, or halo; R7 is C (R2aR2b) COOR3 m is 0 to 3; n is 4 or 5; p is 0 to 2; er is 1 to 6; or a pharmaceutically acceptable salt thereof.
[0007] The application provides a method for treating an infection with the Hepatitis C Virus (HCV) which comprises administering to a patient in need of it a therapeutically effective amount of a compound of Formula I.
[0008] The application provides a composition comprising a compound of Formula I and a pharmaceutically acceptable excipient. Detailed Description of the Invention
[0009] The compounds of Formula I have been shown to inhibit replication of the subgenomic Hepatitis C virus in a hepatoma cell line. These compounds have the potential to be effective as antiviral drugs for the treatment of HCV infections in humans.
[0010] The term "alkyl" as used in this context means a normal or branched chain hydrocarbon residue containing 1 to 12 carbon atoms. Preferably, the term "alkyl" means a normal or branched chain hydrocarbon residue containing from 1 to 7 carbon atoms. Most preferably they are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert. -butyl or pentyl. The alkyl can be unsubstituted or substituted. The substituents are selected from one or more of cycloalkyl, nitro, amino, amino alkyl, amino dialkyl, carbonyl alkyl and cycloalkyl carbonyl.
[0011] The term "cycloalkyl" as used in this context means an optionally substituted cycloalkyl group containing 3 to 7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
[0012] The term "alkoxy" as used in this context means an optionally substituted normal or branched alkyl-oxy group in which the "alkyl" part is as defined above, such as, methoxy, ethoxy, n- propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, tert. -butyloxy, pentyloxy, hexyloxy, heptyloxyl, including their isomers.
[0013] The term "alkoxyalkyl" as used in this context means an alkoxy group as defined above that is attached to an alkyl group as defined above. Examples are methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propyloxypropyl, methoxybutyl, ethoxybutyl, propyloxybutyl, butyloxybutyl, tert. butyloxybutyl, methoxypentyl, ethoxypentyl, propyloxypentyl, including their isomers.
[0014] The term "alkenyl" as used in this context means a substituted or unsubstituted hydrocarbon chain radical having 2 to 7 carbon atoms, preferably from 2 to 4 carbon atoms, and which have one or two olefinic double bonds, preferably an olefinic double bond. Examples are vinyl, 1-propenyl, 2-propenyl (ally) or 2-butenyl (crotyl).
[0015] The term "alkynyl" as used in this context means the substituted or unsubstituted hydrocarbon chain radical which is endowed with 2 to 7 carbon atoms, preferably 2 to 4 carbon atoms, and having a or where possible two triple bonds, preferably a triple bond. Examples are ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.
[0016] The term "hydroxyalkyl" as used in this context means a normal or branched chain alkyl group as defined above in which 1, 2, 3 or more hydrogen atoms are replaced by a hydroxyl group. Examples are hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, hydroxypropyl, hydroxybutyl and the like.
[0017] The term "haloalkyl" as used in this context means a normal or branched chain alkyl group as defined above in which 1, 2, 3 or more hydrogen atoms are replaced by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2- bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl and the like.
[0018] The term "alkylthio" as used in this context means a normal or branched (alkyl) group in which the "alkyl" part is as defined above. Examples are methylthio, ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio or tert.-butylthio.
[0019] The term "aryl" as used in this context means an optionally substituted phenyl and naphthyl (for example, 1-naphthyl, 2-naphthyl or 3-naphthyl). Suitable substituents for aryl can be selected from those named for alkyl, in addition, notwithstanding, halogen, hydroxyl and optionally substituted alkyl, haloalkyl, alkenyl, alkynyl and aryloxy are substituents that can be added to the selection.
[0020] The term "heterocyclyl" as used in this context means optionally substituted saturated, partially unsaturated or aromatic monocyclic, bicyclic or tricyclic systems that contain one or more hetero atoms selected from nitrogen, oxygen and sulfur which they can also be fused to an optionally substituted saturated, partially unsaturated or aromatic monocyclic carbocycle or heterocycle.
[0021] Examples of heterocycles that are suitable are comprised of oxazolyl, isoxazolyl, furyl, tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, 2-thienyl, 3-thienyl, pyrazinyl, otiazolyl, dihydrooxazolyl, pyrimidinyl, tetrazolyl, 1-pyrrolidine 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinonyl, (N-oxide) -pyridinyl, 1-pyrrolyl, 2-pyrrolyl, triazolyl e. g. 1,2,3-triazolyl or 1,2,4-triazolyl, 1-pyrazolyl, 2-pyrazolyl, 4-pyrazolyl, piperidinyl, morpholinyl (eg 4-morpholinyl), thiomorpholinyl (eg 4-thiomorpholinyl), thiazolyl, pyridinyl, dihydrothiazolyl, imidazolidinyl, pyrazolinyl, piperazinyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, thiadiazolyl for example ,. 1,2,3-thiadiazolyl, 4-methylpiperazinyl, 4-hydroxypiperidin-1-yl.
[0022] Substituents that are suitable for heterocyclyl can be selected from those named for alkyl. In addition, however, alkyl, alkenyl, alkynyl, an optionally substituted oxo group (= 0) or aminosulfonyl, which can be added to the selection, are substituents.
[0023] The term "acyl" ("alkylcarbonyl") as used in this context means a group of the formula C (= O) R where R is hydrogen, an unsubstituted or substituted normal or branched chain hydrocarbon residue containing from 1 to 7 carbon atoms or a phenyl group. The most preferred phenyl groups are those in which R is hydrogen, a normal or branched unsubstituted hydrocarbon residue containing 1 to 4 carbon atoms or a phenyl group.
[0024] The term halogen means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine, bromine.
[0025] In the pictorial representation of the compounds given throughout this application, a thickening tapered line (*) indicates a substituent that is above the plane of the ring to which the asymmetric carbon belongs and a dotted line () indicates a substituent that is below the plane of the ring to which the asymmetric carbon belongs.
[0026] The compounds of formula I exhibit stereoisomerism. These compounds can be any isomer of the compound of formula I or mixtures of these isomers. The compounds and intermediates of the present invention that are provided with one or more asymmetric carbon atoms can be obtained as racemic mixtures of stereoisomers that can be converted.
[0027] The compounds of the formula I exhibit tautomerism which means that the compounds of this invention can exist in the form of two or more chemical compounds that are capable of easy interconversion. In many cases it merely means the exchange of a hydrogen atom between two other atoms, for each of which a covalent bond is formed. Tautomeric compounds exist in a mobile equilibrium with each other, so that attempts to prepare the separated substances usually result in the formation of a mixture that shows all the chemical and physical properties that are to be expected based on the component structures.
[0028] The most common type of tautomerism is that involving carbonyl, or keto compounds and unsaturated hydroxyl compounds, or enols. Structural change is the displacement of a hydrogen atom between carbon and oxygen atoms, with the reordering of bonds. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form is the predominant form; in phenols, the enol form is the main component.
[0029] The compounds of the formula I that are basic can form pharmaceutically acceptable salts with inorganic acids such as, hydrochloric acids (for example, hydrochloric acid and hydrobromic acid), sulfuric acid, nitric acid and phosphoric acid, and the like, and the like organic acids (eg, with acetic acid, tartaric acid, succinic acid, fumaric acid, maleic acid, malic acid, salicylic acid, citric acid, methanesulfonic acid and p-toluene sulfonic acid, and the like). The formation and isolation of these acids can be carried out according to methods that are known in the art. HCV inhibitors
[0030] The application provides a compound of Formula I
where: R1 is H, lower haloalkyl, or aryl, where aryl is phenyl or naphthyl, optionally substituted with one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, halo, lower haloalkyl, - N (Rla) 2 , acylamino, -SO2N (Rla) 2, -CORlb, -SO2 (Rlc), -NHSO2 (Rlc), nitro or cyano; each Rla is independently H or lower alkyl; each Rlb is independently -ORla or -N (Rla) 2; each Rlc is lower alkyl; R2a and R2b are (1) independently H, lower alkyl, - (CH2) rN (Rla) 2, lower hydroxyalkyl, -CH2SH, (CH2) S (O) pMe, - (CH2) 3 NHC (= NH) NH2, ( 1H-indol-3-yl) methyl, (1H-indol-4-yl) methyl, - (CH2) mC (= 0) Rlb, aryl and aryl lower alkyl, where aryl can be optionally substituted with one or more hydroxyl , lower alkyl, lower alkoxy, halo, nitro or cyano; (11) Rla is H and R2b and R4 together form (CH2) 3; (111) R2a and R2b together form (CH2) n; or, (ir) R2a and R2b are both lower alkyl; - R3 is H, lower alkyl, lower haloalkyl, phenyl or lower alkyl phenyl; R4 is H, lower alkyl, or R2b and R4 together form (CH2) 3; R5 is H, C (= O) Rlc, C (= O) Rlb, P (= 0) (OR1) (0Rla), or P (= 0) (0R1) (NR4R7); RD is H, methyl, or halo; R7 mn P r is C (R2aR2b) COOR3 is 0 is 4 is 0 is 1 to 3; or 5; up to 2; and up to 6; or a pharmaceutically acceptable salt thereof.
[0031] The application provides a compound of Formula I, where R4 is H.
[0032] The application provides a compound of Formula I, wherein R ° is H or Br.
[0033] The application provides a compound of Formula I, wherein R6 is comprised of H.
[0034] The application provides a compound of Formula I, wherein R6 is comprised of Br.
[0035] The application provides a compound of Formula I, wherein R4 is comprised of H and R6 is comprised of H or Br.
[0036] The application provides a compound of Formula I, wherein R4 is comprised of H and R6 is comprised of Br.
[0037] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl or phenyl.
[0038] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl.
[0039] The application provides a compound of Formula I, wherein R1 is comprised of phenyl.
[0040] The application provides a compound of Formula I, wherein R1 is comprised of phenyl and R4 is comprised of H.
[0041] The application provides a compound of Formula I, wherein R1 is comprised of phenyl, R6 is H, and R4 is comprised of H.
[0042] The application provides a compound of Formula I, in
[0043] that R1 is naphthyl on application and R4 is comprised of H. provides a compound of Formula I, in
[0044] that R1 is naphthyl, the application R4 is H and R6 provides is comprised of H. a compound of Formula I, wherein R1 is comprised of naphthyl and R3 is comprised of isopropyl.
[0045] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is H, and R3 is comprised of isopropyl.
[0046] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is H, R6 is H, and R3 is comprised of isopropyl.
[0047] R1 The application provides a compound of Formula I, wherein it is naphthyl, R4 is H, R6 is comprised of H, R-a is H, and R3 is comprised of isopropyl.
[0048] I, wherein R1 the application provides a compound of the Formula is naphthyl, R4 is H, R ° is H, R2a is comprised of H, R2b is methyl, and R3 is comprised of isopropyl.
[0049] I, wherein R 5 The application provides a compound of the Formula is comprised by H.
[0050] I, wherein R1 the application provides a compound of the Formula is comprised of naphthyl and R5 is comprised of H.
[0051] I, wherein R1 the application provides a compound of the Formula is naphthyl, R4 is H, and R5 is comprised of H.
[0052] I, wherein R1 the application provides a compound of the Formula is comprised of naphthyl, R4 is H, R ° is H, and R and comprised by H.
[0053] The application provides a compound of Formula I, wherein R1 for H, and R e is naphthyl, R4 is H, R6 comprised of H. is H, Raa is comprised
[0054] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is comprised of H, R6 is H, Raa is comprised of H, R ~ b is methyl, and R5 is comprised of H.
[0055] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is comprised of H, R6 is H, R2a is H, Rab is methyl, Ra is comprised of isopropyl, and R5 is H.
[0056] The application provides a compound of Formula I, wherein R5 is comprised of C (= O) Rlc.
[0057] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl, R4 is H, R6 is H, R2a is H, R2b is methyl, R3 is comprised of isopropyl, and R5 is comprised of C (= O) Rlc.
[0058] The application provides a compound of Formula I, wherein Rlc is comprised of ethyl.
[0059] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is comprised of H, R6 is H, R2a is comprised of H, R2b is methyl, R3 is comprised of isopropyl, and R5 is comprised of C (= O) CH2CH3.
[0060] The application provides a compound of Formula I, wherein R5 is comprised of P (= 0) (OR1) (NR4R ').
[0061] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl, R4 is H, R ° is H, R2a is comprised of H, R2b is methyl, R3 is comprised of isopropyl, and R5 is comprised of P (= 0) (OR1) (NR4R7).
[0062] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl.
[0063] The application provides a compound of Formula I, wherein R1 is comprised of naphthyl, R4 is H, R6 is comprised of H, R2a is H, R2b is comprised of methyl, R3 is comprised of isopropyl, R5 is P ( = 0) (OR1) (NR4R7), and R1 is comprised of naphthyl.
[0064] The application provides a compound of Formula I, wherein R4 is H and Rz is comprised of CH (CH3) C (= 0) OCH (CH3) 2.
[0065] The application provides a compound of Formula I, wherein R1 is naphthyl, R4 is H, R6 is comprised of H, R ~ d is H, R2b is comprised of methyl, R3 is comprised of isopropyl, R5 is P ( = 0) (0R1) (NR4R '), R1 is naphthyl, R4 is comprised of H and R7 is comprised of CH (CH3) C (= 0) OCH (CH3) 2.
[0066] The application provides a compound that is selected from the group consisting of:



[0067] The application provides a method for treating an infection with Hepatitis C Virus (HCV) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I.
[0068] The application provides the method set out above in this context, which further comprises administering an immune system modulator or an antivirus agent that inhibits HCV replication, or a combination thereof.
[0069] The application provides the method set out above, in which the immune system modulator is comprised of a chemically derived interferon or interferon.
[0070] The application provides the methods set out above, in which the antivirus agent is selected from the group consisting of an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, a primase inhibitor HCV, an HCV fusion inhibitor, and a combination thereof.
[0071] The application provides a method to inhibit HCV replication in a cell, which comprises administering a compound of Formula I.
[0072] The application provides a composition comprising a compound of Formula I and a pharmaceutically acceptable excipient.
[0073] The application provides a use of the compound of Formula I in the manufacture of a drug for the treatment of HCV.
[0074] The application provides a compound, composition, or method as described in this context. Compounds
[0075] Examples of representative compounds covered by the present invention and within the scope of the invention are provided in the following table. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but as being merely illustrative and representative of it.
[0076] In general, the nomenclature used in this patent application is based on AUTONOMTM v.4.0, a Beilstein Institute computerized system for the generation of systematic IUPAC nomenclature. In the event of a discrepancy between an illustrated structure and a name given to that structure, the illustrated structure should be given greater weight. In addition, if the stereochemistry of a structure or part of the structure is not indicated with, for example, solid or dashed lines, the structure or part of the structure should be interpreted as encompassing all of its stereoisomers. TABLE I - illustrates examples of compounds according to generic Formula I.







Synthesis General Schemes
[0078] The methods previously described in this context are described in more detail below:
[0079] Starting material 1 can be prepared according to the procedures described by Sofia, M. J. et al, J. Med. Chem. (2010), 53 (19), 7202-7218 and Clark, J. L. et al, J. Med. Chem. (2005), 48 (17), 5504-5508. sludge followed by elimination of iodide under basic condition can lead to intermediate 3, in which the protection of hydroxyl 3'-with the benzoyl group leads to intermediate 4. The specific stereo reaction of converting intermediate 4 to 5 is the key step. Similar transformation to install a fluoride at the 4 'α position has been described previously by Ajmera, S. et al, J. Med. Chem. (1988), 31 (6), 1094-1098 and Moffatt, J.G. et al, J. Am. Chem. Soc. (1971), 93 (17), 4323-4324. The displacement of the 5 'iodide with sodium benzoate provides intermediate 6. Finally, the deprotection of the benzoyl groups 3', 5 'in intermediate 6 provides the intermediate nucleoside 7 (Scheme 1).
[0080] In the General Schemes set out below, R1 can be H, lower haloalkyl, or aryl, where aryl can be phenyl or naphthyl, optionally substituted by one or more lower alkyl, lower alkenyl, lower alkynyl, lower alkoxyl, halo, haloalkyl lower, - N (Rla) 2, acylamino, -SO2N (Rla) 2, -CORlb, -S02 (Rlc), -NHSO2 (Rlc), nitro or cyano, each Rla can be independently H or lower alkyl, each Rlb can be independently - 0Rla or -N (Rla) 2, each Rlc can be lower alkyl, R2a and R are (r) independently H, lower alkyl, (CH2) rN (Rla) 2, lower hydroxyalkyl, -CH2SH, (CH2) S (0) pMe, - (CH2) 3 NHC (= NH) NH2, (1H-indol-3-yl) methyl, (1H-indol-4-yl) methyl, - (CH2) mC (= 0 ) Rlb, aryl and aryl lower alkyl, where aryl can be optionally substituted by one or more hydroxyl, lower alkyl, lower alkoxy, halo, nitro or cyano; (if) R2a can be H and R2b and R4 together form (CH2) 2; (iff) R2a and R “b together form (CH2) n; or, (fu) R2a and R2b both are lower alkyl, R3 can be H, lower alkyl, lower haloalkyl, phenyl or phenyl lower alkyl, R4 can be H, lower alkyl, or R2b and R4 together form (CH2) 3 , R5 can be H, C (= O) Rlc, C (= O) Rlb, P (= 0) (OR1) (0Rla), or P (= 0) (0R1) (NR4R7), R6 can be H, methyl, or halo, R7 can be 0 (R2aR2b) COOR3, m can be 0 to 3, n can be 4 or 5, p can be 0 to 2, r can be 1 to 6. Scheme 1.

[0081] Nucleoside 7 can also be smoothly converted to intermediate 5'-halogen 8 by reaction with NCS, NBS, or NIS under appropriate conditions (Scheme 2). Scheme 2.

[0082] The phosphoramidate compounds of the present invention can be prepared by condensing nucleosides 7 or 8 with a phosphochlorhydrate compound 11 suitably substituted in the presence of a strong base (Scheme 3). Condensation can be carried out on unprotected nucleosides 7 or 8. The coupled product 12 in formula I can be further derivatized into product 13. The two compounds 12 or 13 in formula .1 are obtained as a mixture of two diastereomers initially under the coupling reaction and can be separated into their corresponding chiral enantiomers through chiral column, chiral HPLC, or chiral SFC chromatography. Scheme 3.
Dosage and Administration:
[0083] As shown in the previous table, the compounds of formula I have the potential to be effective as antiviral drugs for the treatment of HCV infections in humans, or are metabolized to a compound that exhibits this activity.
[0084] According to another embodiment of the invention, the active compound or its derivative or salt can be administered in combination with another anti-virus agent, such as an anti-hepatitis agent, including those of Formula I. When the active compound or its derivative or its salt are administered in combination with another antivirus agent the activity can be increased on the parent compound. This can be easily assessed by preparing the derivative and testing its anti-HCV activity according to the method described in this context.
[0085] The administration of the active compound can vary from continuous (intravenous drip) to several daily oral administrations (for example, QID) and can include oral, topical parenteral, intramuscular, intravenous, subcutaneous, transdermal (which can include an intensifying agent) oenetration), buccal and suppository administration, among other routes of administration.
[0086] Derivatives of 4'-F nucleosides substituted in the same way as their pharmaceutically usable salts, can be used as drugs in the form of any pharmaceutical formulation. The pharmaceutical formulation can be administered enterally, either orally, for example, in the form of tablets, coated tablets, pills, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions, or rectally, for example, in the form of suppositories. They can also be administered parenterally (intramuscularly, intravenously, subcutaneously or by intradermal injection or infusion techniques), for example, in the form of injectable solutions, nasally, for example, in the form of nasal sprays or sprays of inhalation, topical photrma, and so on.
[0087] For the manufacture of pharmaceutical preparations, the 4'-substituted nucleoside derivatives, in the same way as their pharmaceutically usable salts, can be formulated with an inorganic or organic excipient, therapeutically inert, for the production of tablets, coated tablets, pills, hard and soft gelatin capsules, solutions, emulsions or suspensions.
[0088] The compounds of formula I can be formulated by mixing with a pharmaceutically acceptable carrier. For example, the compounds of the present invention can be administered orally as pharmacologically acceptable salts. Because the compounds of the present invention are most often soluble in water, they can be administered intravenously in physiological saline (for example, buffered to a pH of about 7.2 to 7.5). Conventional buffers such as phosphate, bicarbonates or citrates can be used for this purpose. of course, the person ordinarily skilled in the art can modify the formulations within the teachings of the report to provide numerous formulations for a specific route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity. In particular, the modification of the present compounds to make them more soluble in water or another vehicle, for example, can easily be accomplished by minor modifications (saline formulation, esterification, and the like) that are widely known to the person normally skilled in the art. It is also within the normal experience of one normally skilled in the art to modify the administration route and dosage regimen of a specific compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect on patients.
[0089] For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, although other ingredients including those that aid dispersion may be included. Of course, where sterile water must be used and kept sterile, the compositions and carriers must also be sterilized. Injectable suspensions can also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
[0090] Excipients suitable for tablets, coated tablets, dragees and hard gelatin capsules are, for example, lactose, corn starch and its derivatives, talc, and stearic acid or its salts.
[0091] If desired, tablets or capsules can be enteric coated or prepared for sustained release using standard techniques.
[0092] Excipients that are suitable for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solids and vegetable oils, waxes, fats, semi-solid polyols and liquids.
[0093] Excipients that are suitable for injection solutions are, for example, water, saline, alcohols, polyols, glycerin or vegetable oils.
[0094] Excipients that are suitable for suppositories are, for example, natural and hardened oils, waxes, fats, liquid or semi-liquid polyols.
[0095] Excipients that are suitable for solutions and syrups for enteric use are, for example, water, polyols, sucrose, invert sugar and glucose.
[0096] The pharmaceutical preparations of the present invention can also be provided as controlled release formulations or other suitable formulations.
[0097] Pharmaceutical preparations may also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, dyes, flavorings, salts for adjusting osmotic pressure, buffers, concealers or antioxidants.
[0098] Pharmaceutical preparations can also contain other therapeutically active agents that are known in the art.
[0099] The dosage may vary within wide limits and will, of course, be adjusted to the individual requirements in each specific case. For oral administration, a daily dosage between about 0.01 and about 100 mg / kg of body weight per day should be appropriate in monotherapy and / or combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg / kg body weight, more preferably from 0.1 to about 100 mg / kg body weight and most preferably from 1.0 to about 100 mg / kg and body weight per day. A typical preparation will contain between about 5% to about 95% active compound (w / w). The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day.
[00100] In certain pharmaceutical dosage forms, prodrug forms of the compounds are preferred, especially those that include acylated derivatives (acetylated or others), pyridine esters and various salt forms of the present compounds. The person ordinarily skilled in the art will recognize how to easily modify the present compounds into prodrug forms to facilitate the distribution of the active compounds to a targeted location within the human or patient organism. The person normally versed in the technique will also take advantage of the favorable pharmacokinetic parameters of the prodrug forms, where applicable, in the distribution of the present compounds to the target site within the host or patient organism to maximize the intended effect of the compound. Indications and Treatment Methods
[00101] The compounds of the invention and their isomeric forms and their pharmaceutically acceptable salts are of use in the treatment and prevention of HCV infection.
[00102] The application provides a method for treating a Hepatitis C Virus (HCV) infection which comprises administering to a patient in need of it a therapeutically effective amount of a compound of any one of Formula I.
[00103] The application provides a method for inhibiting HCV replication in a cell comprising administering a compound of any one of Formula I. Combination Therapy
[00104] The compounds of the invention and their isomeric forms and their pharmaceutically acceptable salts are useful in the treatment and prevention of HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the life cycle HCV. The classes of compounds of utility in the invention include, without limitation, all classes of HCV antiviral drugs.
[00105] For combination therapies, mechanistic classes of agents that may be of use when combined with the compounds of the invention include, for example, nucleoside and non-nucleoside inhibitors of HCV polymerase, protease inhibitors, helicase inhibitors, inhibitors NS4B and medicinal agents that functionally inhibit the internal ribosomal entry site (IRES) and other drugs that inhibit cell attachment or HCV virus entry, HCV RNA translation, HCV RNA transcription, HCV replication or maturation, assembly or virus release. Specific compounds in these classes and of utility in the invention include, but are not limited to, macrocyclic, heterocyclic and linear HCV protease inhibitors, such as telaprevir (VX-950), boceprevir (SCH-503034), narlaprevir (SCH -9005 18), ITMN-191 (R-7227), TMC-435350 (aka TMC-435), MK-7009, BI-201335, BI-2061 (ciluprevir), BMS-650032, ACH-1625, ACH-1095 (HCV NS4A protease co-factor inhibitor), VX-500, VX-8 13, PHX-1766, PHX2054, IDX-136, IDX-3 16, ABT-450 EP-0 13420 (and the like) and GBV -376; Nucleoside HCV polymerase inhibitors (replicase) useful in the invention include, but are not limited to, R7128, PSI-785 1, IDX-184, IDX-102, R1479, UNX-08 189, PSI- 6130 , PSI-938 and PSI-879 and several other nucleoside and nucleotide analogs and HCV inhibitors that include (but are not limited to) those derived as modified 2'-C-methyl nuclei (t) nuclei ( t) modified 4'-aza ids, and nuclei (t) modified 7'-aza ides. Non-nucleoside HCV polymerase (replicase) inhibitors useful in the invention include, but are not limited to, HCV-796, HCV-371, VCH-759, VCH-916, VCH-222, ANA-598 , MK-3281, ABT-333, ABT-072, PF-00868554, BI-207127, GS-9190, A-837093, JKT-109, GL-59728 and GL-60667.
[00106] Furthermore, the compounds of the invention can be used in combination with cyclophilin and immunophilin antagonists (for example, without limitation, DEBIO, NM-811 compounds in the same way as cyclosporine and its derivatives), kinase inhibitors, heat shock protein inhibitors (for example, HSP90 and HSP70), other immune modulating agents that may include, without limitation, interferons (-alpha, -beta, -omega, -gamma, lambda or synthetic) such as Intron A, Roferon-A, Canferon-A300, Advaferon, Infergen, Humoferon, Sumiferon MP, Alfaferone, IFN-β, Feron and the like; interferon compounds derived from polyethylene glycol (pegylated), such as, interferon-α-2a PEG (Pegasys), interferon-α-2b PEG (PEGIntron), IFN-a-con- pegylated and the like; long-acting formulations and derivatives of interferon compounds such as albumin-fused interferon, Albuferon, Locteron, and the like; interferons with various types of controlled delivery systems (for example, ITCA-638, omega-interferon delivered by the HARD subcutaneous delivery system); compounds that stimulate the synthesis of interferon in cells, such as resiquimod and the like; interleukins; compounds that enhance the development of type 1 T cell helper response, such as SCV-07 and the like; TOLL-like receptor agonists, such as CpG-10101 (actilon), isotorabine, ANA773 and the like; thymosin a-1; ANA-245 and ANA-246; histamine dihydrochloride; propagermanium; tetrachlorodecaoxide; ampligen; IMP-321; KRN-7000; antibodies such as civacir, XTL-6865 and the like and prophylactic and therapeutic vaccines such as InnoVac C, HCV E1E2 / MF59 and the like. In addition, any of the methods described above that involve the administration of an NS5A inhibitor, a Type I interferon receptor agonist (for example, an IFN-a) and a Type II interferon receptor agonist (for example , an IEN-y) can be increased by administering an effective amount of a TNF-a antagonist. Exemplary, non-limiting TNF-a antagonists that are suitable for use in these combination therapies include ENBREL, REMICADE, and HUMIRA.
[00107] Furthermore, the compounds of the invention can be used in combination with antiprotozoa and other antivirals considered to be effective in the treatment of HCV infection such as, without limitation, the prodrug nitazoxanide. Nitazoxanide can be used as an agent in combination with the compounds that are exposed in this invention in the same way as in combination with other agents useful in the treatment of HCV infection, such as peginterferon α-2a and ribavirin.
[00108] The compounds of the invention can also be used with alternative forms of interferons and pegylated interferons, ribavirin or its analogs (for example, tarabavarin, levoviron), microRNA, small interference RNA compounds (for example, SIRPLEX-140- N and the like), nucleotide or nucleoside analogs, immunoglobulins, hepatoprotectors, anti-inflammatory agents and other NS5A inhibitors. Inhibitors of other targets in the HCV life cycle include NS3 helicase inhibitors; NS4A cofactor inhibitors; antisense oligonucleotide inhibitors, such as ISIS-14803, AVI-4065 and the like; Vector-encoded short-clip RNA (shRNA); HCV specific ribozymes such as, heptazyme, RPI, 13919 and the like; entry inhibitors such as HepeX-C, HuMax-HepC and the like; alpha glucosidase inhibitors, such as, celgosivir, UT-231B and the like; KPE-02003002 and BIVN 401 and IMPDH inhibitors. Other illustrative HCV inhibitory compounds include those that are set out in the following publications: U.S. Patent Nos. 5,807,876; 6,498,178; 6,344,465; and 6,054,472; PCT No. patent application publications. WC97 / 40028; WO98 / 4038 1; WOOO / 56331, W002 / 04425; W003 / 007945; W003 / 010141; W003 / 000254; WOOl / 32153; WO00 / 06529; WOOO / 18231; WO00 / 10573; WO00 / 13708; WO01 / 85172; WO03 / 037893; WO03 / 037894; WO03 / 037895; W002 / 100851; W002 / 100846; WO99 / 01582; WO00 / 09543; WO02 / 18369; WO98 / 17679, WO00 / 056331; WO98 / 22496; WO99 / 07734; W005 / 073216, WO05 / 073195 and W008 / 021927.
[00109] In addition, combinations of, for example, ribavirin and interferon, can be administered as multiple combination therapy with at least one of the compounds of the invention. The present invention is not limited to the classes or compounds mentioned above and considers known and new compounds and combinations of biologically active agents. It is intended that the combination therapies of the present invention include any chemically compatible combination of a compound of this inventive group with other compounds located outside the group of the invention, insofar as the combination does not eliminate the antiviral activity of the compound of this inventive group or the activity anti-virus of the pharmaceutical composition itself.
The combination therapy can be sequential, that is, treatment with one agent first and then a second agent (for example, where each treatment comprises a different compound of the invention or where one treatment comprises a compound of the invention and the other comprises one or more biologically active agents) or it can be a treatment with both agents at the same time (simultaneously). Sequential therapy may include a reasonable period after the completion of the first therapy before the second therapy is initiated. The treatment with the two agents at the same time can be in the same daily dose or in separate doses. Combination therapy need not be limited to two agents and can include three or more agents. Dosages for both simultaneous and sequential combination therapy will depend on the rates of absorption, distribution, metabolism and excretion of the components of the combination therapy as well as other factors known to the person skilled in the art. Dosage values will also vary according to the severity of the condition that must be relieved. It should also be understood that for any specific patient, dosing regimens and schedules can be adjusted over time according to individual need and the criteria of the person skilled in the administration technique or supervision of the administration of the combination therapy.
[00111] The application provides a method for the treatment of a Hepatitis C virus (HCV) infection which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any one of Formula I.
[00112] The application provides the method set out above, which further comprises administering an immune system modulator or an antivirus agent that inhibits HCV replication, or a combination thereof.
[00113] The application provides the method mentioned earlier, in which the immune system modulator is comprised of a chemically derived interferon or interferon.
[00114] The application provides the methods set out above, in which the antivirus agent is selected from the group consisting of an HCV protease inhibitor, an HCV polymerase inhibitor, an HCV helicase inhibitor, a primase inhibitor HCV, an HCV fusion inhibitor, and a combination thereof. EXAMPLES
[00117] Abbreviations used in the application include: acetyl (Ac), acetic acid (HOAc), azo-bis-isobutyrylnitrile (AIBN), 1-N-hydroxybenzotriazole (HOBt), atmospheres (Atm), high pressure liquid chromatography (HPLC), 9-borabicyclo [3.3.1] nonane (9-BBN or BBN), methyl (Me), tert-butoxycarbonyl (Boc), acetonitrile (MeCN), di-tert-butyl pyrocarbonate or boc anhydride (BOC2O) , 1- (3-dimethylaminopropyl) -3-ethylacarbodiimide hydrochloride (EDCI), benzoyl (Bz), benzyl (Bn), m-chloroperbenzoic acid (MCPBA), butyl (Bu), methanol (MeOH), benzyloxycarbonyl (cbz or Z), melting point (mp), carbonyl diimidazole (GDI), MeSO2- (mesyl or Ms), 1,4-diazabicyclo [2.2.2] octane (DABCO), mass spectrum (ms), sulfur diethylamino trifluoride (DAST), methyl t-butyl ether (MTBE), dibenzylidene-acetone (Dba), N-carboxyanhydride (NCA), 1,5-diazabicyclo [4.3.0] non-5-ene (DBN), N-bromosuccinimide ( NBS), 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), 1,2-dicl oroethane (DCE), pyridinium chlorochromate (PCC), N, N'-dicyclohexylcarbodiimide (DCC), pyridinium dichromate (PDC), dichloromethane (DCM), propyl (Pr), diethyl azodicarboxylate (DEAD), phenyl ( Ph), diisopropylazodicarboxylate, DIAD, pounds per square inch (psi), diisopropylethylamine (DIPEA), pyridine (pyr), diisopropyl aluminum hydride, DIBAL-H, room temperature, rt or RT, N, N-dimethyl acetamide (DMA), tert-butyldimethylsilyl or t-BuMe2Si, (TBDMS), 4-N, N-dimethylaminopyridine (DMAP), triethylamine (Et3N or TEA), N, N-dimethylformamide (DMF) , triflate or CF3SO2- (Tf), dimethyl sulfoxide (DMSO), trifluoroacetic acid (TFA), 1, 1'-bis- (diphenylphosphino) ethane (dppe), 2,2,6,6-tetramethyl-heptane-2, 6-dione (TMHD), 1,1'-bis- (diphenylphosphino) ferrocene (dppf), thin layer chromatography (TLC), ethyl acetate (EtOAc), tetrahydrofuran (THE), diethyl ether (Et2O), trimethylsilyl or Me3Si (TMS), ethyl (Et), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), dissilaz year lithium hexamethyl (LiHMDS), 4-Me-C6H4SO2- or tosyl (Ts), iso-propyl (i-Pr), N-urethane-N-carboxyl hydride (UNCA), ethanol (EtOH). The conventional nomenclature that includes the prefixes normal (n), iso (1-), secondary (see-), tertiary (tert-) and neo have their usual meaning when used with an alkyl portion. (J. Rigaudy and D. P. Klesney, Nomenclature in Organic Chemistry, IUPAC 1979 Pergamon Press, Oxford.). General conditions
[00118] The compounds of the invention can be prepared by a variety of methods set out in the illustrative synthetic reactions described below in the Examples section.
[00119] The starting materials and reagents used in the preparation of these compounds in general are either found available from commercial suppliers, such as Aldrich Chemical Co., or are prepared by methods known to those skilled in the art following the procedures set out in references such as Fieser and Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York, 1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, Elsevier Science Publishers, 1989, Volumes 1-5 and Suppiementals; and Organic Reactions, Wiley & Sons: New York, 1991, Volumes 1-40. It should be appreciated that the synthetic reaction schemes illustrated in the Examples section are merely illustrative of some methods by which the compounds of the invention can be synthesized, and various modifications to these synthetic reaction schemes can be carried out and will be suggested to the skilled person in the art having referred to the exposure contained in this application.
[00120] The starting materials and intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, which include, but are not limited to, filtration, distillation, crystallization, chromatography, and the like . These materials can be characterized using conventional means, including physical constants and spectral data.
[00121] Unless otherwise specified, the reactions described in this context are typically conducted under an inert atmosphere under atmospheric pressure and over a temperature range ranging from -78 ° C to about 150 ° C, often from about 0 ° C to about 125 ° C, and most often and conveniently at about room temperature, for example, about 20 ° C.
[00122] Various substituents on the compounds of the invention can be present in the starting compounds, added to any of the intermediates or added after the formation of the final products by means of known methods of substitution or conversion reactions. If the substituents themselves are reactive, then the substituents themselves can be protected according to techniques known in the art. A variety of protecting groups are known in the art and can be employed. Examples of many of the possible groups can be found in "Protective Groups in Organic Synthesis" by Green et al., John Wiley and Sons, 1999. For example, nitro groups can be added via nitriding and the nitro group can be converted to other groups, such as, amino by means of reduction, ehalogen by means of diazotization of the amino group and replacement of the diazo group by halogen. Acyl groups can be added by means of Friedel-Crafts acylation. The acylation groups can then be transformed to the corresponding alkyl groups by various methods, including Wolff-Kishner reduction and Clemmenson reduction. The amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxyl groups can be alkylated to form the corresponding ethers. Primary alcohols can be oxidized by means of oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxides to form ketones. Thus, substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product, including isolated products. Preparation Examples Preparation 1. Preparation of intermediate 1 - ((2R, 3R, 4R, 5S) -3-fluoro -4-hydroxy -5 - (iodomethyl) -3-methyl-tetrahydrofuran -2 - yl) pyrimidine -2, 4 (1H, 3H) -diral chiral
MW 370.12 C10H12FIN2θ4
[00123] 1 - ((2R, 3R, 4R, 5R) -3-fluoro -4 -hydroxy -5 - hydroxymethyl -3-methyl-tetrahydro-furan -2 -yl) -1H - pyrimidine -2,4 -dione chiral (6.14 g, 23.6 mmol), PPh3 (9 g, 34.4 mmol), imidazole (2.4 g, 34.4 mmol) and anhydrous THF (100 ml) were added to a vial of 3- bottlenecks (500 ml), the mixture was subjected to stirring under 20 ° C under nitrogen atmosphere for 20 min. Then I2 (6.6 g, 26 mmol) dissolved in anhydrous THF (100 ml) was added to the mixture dropwise under 20 ° C over 30 min., After the addition the whole mixture was subjected to stirring under 20 ° C under nitrogen atmosphere for 18 h. TLC showed that the SM was consumed, then water (50 ml) was added, the mixture was extracted by EA (150 mlx3), the organic layer was washed with brine, subjected to drying over Na3SO4, the solvent removed by means of reduced pressure , the residue was purified by silica gel column chromatography (DCM: MeOH = 100: 1 to 50: 1) to provide the title compound as a white solid (8.2 g, 94%). LC-MS (M + H) + = 371.0 Preparation 2. Preparation of intermediate 1 - ((2R, 3R, 4R) -3-fluoro -4 - hydroxy -3-methyl -5-methylene-tetrahydrofuran -2 - il) pyrimidine -2,4 (1H, 3H) -diral chiral
MW 242.21 CioHnFN204
[00124] 1 - ((2R, 3R, 4R, 5S) -3-fluoro -4-hydroxy -5 - (iodomethyl) -3-methyl -tetraid rofuran -2 -yl) pyrimidine - 2.4 (1H, 3H ) -dione Chiral (8.2 g, 22 mmol) was dissolved in MeOH (100 ml) and NaOMe (3.73 g, 69 mmol) was added thereto under nitrogen atmosphere, after the addition the mixture was heated to 65 ° C and submitted stirring under nitrogen for 14 h. TLC showed that the SM was consumed, then the mixture was cooled to rt, IR-120 ion exchange resin (H) was added to adjust the pH to 8, filtered and the colvent removed by reduced pressure, the product crude was purified by column chromatography on silica gel (DCM: MeOH = 15: 1) to provide the title compound as a white solid (3.3 g, 59%). LC-MS (M + H) + = 243.1 Preparation 3. Preparation of acid intermediate (3R, 4R, 5R) -5 - (2,4 - dioxo -3,4-dihydro -2H -pyrimidin -1 -yl) - 4-fluoro -4 - methyl -2-methylene-tetrahydro-furan -3-yl benzoic ester
MW 34 6.32 CnH15FN2O5
[00125] To a mixture of 1 - ((2R, 3R, 4R) -3-fluoro-4-hydroxy-3-methyl-5-methylene-tetrahydrofuran -2-yl) pyrimidine-2,4 (1H, 3H) chiral dione (18.3 g, 75.6 mmol) and DMAP (27.7 g, 227 mmol) in anhydrous THF (900 ml) under 0 ° C BzCl (15.9 g, 113.4 mmol) was added dropwise drop. The reaction mixture was stirred at 0 ° C for 0.5 h, then sat. NaHCCn to temper the reaction. The mixture was extracted with EA (300 mlx3). The combined organic extract was washed with H2O, brine, dried over Na2SO4, and concentrated. The residue was purified by silica gel column chromatography (DCM: MeOH = 160: 1 to 120: 1) to provide the title compound as a white solid (17 g, 65%). LC-MS (M + H) + = 347.1 Preparation 4. Preparation of the intermediate (2R, 3S, 4R, 5R) -5 - (2,4-dioxide - 3,4-dihydropyrimidin -1 (2H) -il ) -2,4 -difluor -O -2 - (iodomethyl) -4-methyl-tetrahydrofuran -3 -yl benzoate
MW 492.22 C17H15F2IN2O5
[00126] To a mixture of (3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -4-fluoro-4-methyl-2- methylene tetrahydro-furan-3-yl chiral benzoic ester (17 g, 49 mmol) and AgF (31 g, 245 mmol) in anhydrous THF (600 ml) under 0 ° C a solution of THF (600 ml) of I2 (24.8 g, 98 mmol) dropwise. After the addition was complete, the reaction mixture was warmed to room temperature and subjected to stirring for 3 h. TLC analysis indicated that the starting material was completely consumed and the formation of the desired product. The reaction was quenched with aqueous NaS2O2 solution (5%, 300 ml). The mixture was extracted using EA (350 mlx3). The combined organic extract was washed with brine, dried over Na2SO4, and concentrated. The residue was pyrified by column chromatography on silica gel (DCM: MeOH = 120: 1) to provide the title compound as a white solid (11 g, 45%). LC-MS (M + H) + = 493.0 Preparation 5. Preparation of the intermediate (2R, 3S, 4R, 5R) -5 - (2,4-dioxide - 3,4-dihydropyrimidin -1 (2H) -il ) -2,4 -difluor -O -2 - benzoylmethyl -4-methyl-tetrahydrofuran -3 -yl chiral benzoate
MW 486.46 C24H20F2N2O7
[00127] (2R, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -yl) -2,4-difluor-0-2- (iodomethyl) - 4- chiral methyl-tetrahydrofuran-3-yl benzoate (0.56 g, 1.15 mmol), sodium benzoate (0.825 g, 5.73 mmol) and 18-crown-6 (0.03 g, 0.115 mmol) were suspended in DMSO (20 ml), the solution was heated to 100 ° C and stirred under nitrogen for 18 h, then cooled to rt, water (30 ml) was added to it, the mixture was extracted using EA (30 mlx3), the organic layer was washed with H2O, brine and H2O, the solvent removed under reduced pressure, the residue was purified by column chromatography on silica gel (PE: EA = 1: 2) to provide the title compound as a colorless oil (0.34 g, 61%). LC-MS (M + Na) + = 509.1 Preparation 6. Preparation of intermediate 1 - ((2R, 3R, 4S, 5S) -3,5-difluoro -4-hydroxy -5 - (hydroxymethyl) -3 - methyl -tetrahydrofuran -2 -yl) pyrimidine -2,4 (1H, 3H) -diral chiral
MW 2 7 8.21 Ci0H12F2N2θ5
[00128] (2R, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -11) -2,4-difluor-0-2-benzoylmethyl-4- Chiral methyl-tetrahydrofuran-3-yl benzoate (0.34 g, 0.7 mmol) was dissolved in methanol, and a solution of ammonia in methanol (7 N, 20 ml) was added. The reaction mixture was stirred at room temperature overnight. The mixture was concentrated, and the residue was purified by column chromatography on silica gel (DCM: MeOH = 20: 1) and pre-HPLC to provide the title compound as a white solid (0.074 g, 38 %). LC-MS (M + H) + = 279.1; : H NMR (300MHz, DMSO-d6) δ 11,575 (s, 1 H), 7, 666-7, 639 (d, 1 H, J = 8.1 Hz), 6, 324-6, 266 (d, 1 H, J = 17.4 Hz), 6, 056-6, 037 (d, 1 H, J = 5.7 Hz), 5.821 (brs, 1 H), 5.713-5.686 (d, 1H, J = 8.1 Hz), 4.057-4.023 (m, 1H), 3.636 (s, 2 H), 1.313-1.238 (d, 3H, J = 22.5 Hz) Preparation 7. Preparation of intermediate 5 -bromine -1 - ((2R, 3R, 4S, 5S) - 3,5-difluoro -4-hydroxy -5-hydroxymethyl -3-methyl-tetrahydro-furan-2-yl) -1H -pyrimidine -2,4 -diral chiral
MW 357.11 C1oH11BrF2N205
[00129] In a 2 ml microwave vial, 1- ((2R, 3R, 4S, 5S) -3,5-difluoro-4-hydroxy-5- (hydroxymethyl) -3-methyl-tetrahydrofuran-2-yl ) chiral pyrimidine-2,4 (1H, 3H) -dione (70 mg, 0.252 mmol), and NBS (67.2 mg, 0.377 mmol), were dissolved in DMF (0.7 ml). The mixture was capped and heated to microwave irradiation under 80 ° C for 10 min. LC / MS analysis indicated that the starting material was completely consumed and the formation of the desired product in the form of the only main product. The solvent was evaporated, and the residue was purified by means of a 2x4g silica gel cartridge, eluted with 0.70% EtOAc in hexanes to provide the title compound as a white solid (94 mg, 90%) MS (M) + = 358; rH NMR (300 MHz, CD3OD): δ (ppm) 8.41 (s, 1H), 6.40-6.35 (d, 1H), 4.28- 4.18 (m, 1H), 3, 80-3.76 (d, 2H), 1.45-1.37 (d, 3H) Example 1. Preparation of (S) -2 isopropyl acid ester - {[((2S, 3S, 4R, 5R) - 5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy-4-methyl-tetrahydro-furan -2 -ylmethoxy] -phenoxy -phosphorylamino } –Propionic
1-1 MW 547.45 C22H28F2N3O9P Step A.
[00130] (S) -isopropyl hydrochloride 2-aminopropanoate (Oakwood, 500 mg, 2.98 mmol) and phenyl phosphorodichloride (Aldrich, 662 mg, 2.98 mmol) was suspended in anhydrous DCM (25 ml) . The reaction was cooled to -78 ° C. Triethylamine (604 mg, 830 pl, 5.97 mmol) was added dropwise. The reaction mixture was stirred under -78 ° C for 1 h, then allowed to warm to room temperature and subjected to stirring overnight. The solvent was removed, the residue was washed with anhydrous ether. The filtrate was concentrated to provide crude (2S) -isopropyl 2- (chloro (phenoxy) phosphorylamino) propanoate as a light yellow oil (0.8 g, 88%) and used without further purification. Step B.
[00131] To a solution of 1 - ((2R, 3R, 4S, 5S) -3,5-difluoro-4-hydroxy-5- (hydroxymethyl) -3-methyltetrahydrofuran-2-yl) pyrimidine-2,4 ( 1H, 3H) chiral dione (42 mg, 151 pmol) prepared in Preparation 6 in THF (8.00 ml) a solution of THF (Aldrich, 1 M) of tert-butylmagnesium chloride (377 pl, 377 pmol) was added ) dropwise. The mixture was stirred at room temperature for 15 min., Followed by the addition of a THF solution (0.5 M) of (2S) -isopropyl 2- (chloro (phenoxy) phosphorylamino) propanoate (755 pl, 377 pmol) . The reaction mixture was stirred at room temperature for 1 h, followed by the addition of THF (Aldrich, 1 M) solution of tert-butylmagnesium chloride (189 pl, 189 pmol) and THF solution (0.5 M ) of (2S) -isopropyl 2- (chloro (phenoxy) phosphorylamino) propanoate (378 pl, 189 pmol). The reaction mixture was then stirred at room temperature for 2 h. Methanol (2 ml) was added to end the reaction. The mixture was purified by means of flash chromatography (silica gel, 0-15% MeOH in DCM) and dried in vacuo to provide the title compound as a light yellow solid (18 mg, 22%) . LC-MS (M + H) + = 548.1 Example 2 Preparation of isopropyl ester of (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3, 4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] - (naphthalen -1 -yloxy) -phosphorylamino] - propionic
1-2 MW 597.51 C26H30F2N3O9P Step A.
[00132] Naphthalen-l-ol (Aldrich, 1.5 g, 10.4 mmol) and phosphorus oxychloride (V) (Aldrich, 1.6 g, 0.97 ml, 10.4 mmol) were suspended in anhydrous ether (37.5 ml), and the temperature was cooled to -78 ° C. Triethylamine (1.05 g, 1.45 ml, 10.4 mmol) was added dropwise and the reaction mixture was stirred at -78 ° C for 1 h. The reaction mixture was warmed to room temperature and subjected to stirring overnight. The mixture was filtered, and the filtrate was concentrated to provide crude naphthalen-1-yl phosphorus dihydrochloride as a light yellow oil (2 g, 74%) and used for the next step without any further purification. Step B.
[00133] (S) -isopropyl 2-aminopropanoate hydrochloride (Oakwood, 1.28 g, 7.64 mmol) and naphthalen-1-yl phosphorus dihydrochloride (2 g, 7.66 mmol) were suspended in anhydrous DCM (35 ml). The reaction was cooled to -78 ° C. Triethylamine (1.55 g, 2.13 ml, 15.3 mmol) was added dropwise. The reaction mixture was stirred at -78 ° C for 1 h, then warmed to room temperature and subjected to stirring for 5 h. The solvent was removed, and the residue was washed with anhydrous ethyl ether and filtered. The filtrate was concentrated to provide crude (2S) -isopropyl 2- (chlorine (naphthalen-1-yloxy) phosphorylamino) propanoate as a light yellow oil (2.5 g, 92%) and used without further purification. And slap C.
[00134] To a solution of 1 - ((2R, 3R, 4S, 5S) -3,5-difluoro-4-hydroxy-5- (hydroxymethyl) -3-methyltetrahydrofuran-2-yl) pyrimidine-2,4 ( 1H, 3H) chiral dione (150 mg, 539 pmol) prepared in Preparation 6 in THF (24 ml) a solution of THF (Aldrich, 1 M) of tert-butylmagnesium chloride (1.35 ml, 1, 35 mmol) dropwise. The mixture was stirred at room temperature for 15 min, followed by the addition of THF solution (0.5 M) of (2S) -isopropyl 2- (chlorine (naphthalen-1-yloxy) phosphorylamino) propanoate (2.7 ml, 1.35 mmol). The reaction mixture was stirred at room temperature for 1 h, then an additional THF solution (Aldrich, 1 M) of tert-butylmagnesium chloride (0.68 ml, 0.68 mmol) and THF solution (0, 5 M) of (2S) -isopropyl 2- (chloro (naphthalen-1-yloxy) phosphorylamino) propanoate (1.35 ml, 0.68 mmol) was added. The reaction mixture was then stirred at room temperature for 3 h. Methanol (6 ml) was added to stop the reaction. The mixture was purified by flash chromatography (silica gel, 0.15% MeOH in DCM) and subjected to drying in vacuo to provide the title compound as a white solid (0.2 g, 62%). LC-MS (MH) 4 = 596.0 Example 3 Preparation of isopropyl ester of (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4 - dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] - (naphthalen -2-yloxy) -phosphorylamino] - propionic
1-3 MW 597.51 C26H30F2N3O9P Step A.
[00135] Naftalen-2-ol (Aldrich, 2 g, 13.9 mmol) and phosphorus oxychloride (V) (Aldrich, 2.13 g, 1.29 ml, 13.9 mmol) were suspended in ether anhydrous (50 ml), and the temperature was cooled to -78 ° C. Triethylamine (1.4 g, 1.93 ml, 13.9 mmol) was added dropwise and the reaction mixture was stirred at -78 ° C for 1 h. The reaction mixture was warmed to room temperature and subjected to stirring overnight. The mixture was filtered, and the filtrate was concentrated to provide crude naphthalen-2-yl phosphorodichlorohydrate as a light yellow oil (2.5 g, 69%) and used for the next step without further purification. Step B.
[00136] (S) -isopropyl 2-aminopropanoate hydrochloride (Oakwood, 500 mg, 2.98 mmol) and naphthalen-2-yl phosphorodichlorohydrate (724 mg, 2.98 mmol) were suspended in anhydrous DCM (25 ml ). The reaction was cooled to -78 ° C. Triethylamine (604 mg, 830 pl, 5.97 mmol) was added dropwise. The reaction mixture was stirred at -78 ° C for 1 h, then allowed to warm to room temperature and subjected to stirring for 5 h. The solvent was removed, and the residue was washed with anhydrous ethyl ether and filtered. The filtrate was concentrated to provide crude (2S) -isopropyl 2- (chlorine (naphthalen-2-yloxy) phosphorylamino) propanoate as a light yellow oil (0.8 g, 75%) and used without further purification . Step C.
[00137] To a solution of 1 - ((2R, 3R, 4S, 5S) -3,5-difluoro-4-hydroxy-5- (hydroxymethyl) -3-methyltetrahydrofuran-2-yl) pyrimidine-2,4 ( 1H, 3H) chiral dione (60 mg, 216 pmol) prepared in Preparation 6 in THF (8 ml) a THF solution (Aldrich, 1 M) of tert-butylmagnesium chloride (539 pl, 539 pmol) was added dropwise drop. The mixture was stirred at room temperature for 15 min. followed by the addition of THF solution (0.5 M) of (2S) -isopropyl 2- (chlorine (naphthalen-2-yloxy) phosphorylamino) propanoate (1.08 ml, 539 pmol). The reaction mixture was stirred at room temperature for 1 h, then additional THF solution (Aldrich, 1 M) of tert-butylmagnesium chloride (270 pl, 270 pmol) and THF solution (0.5 M) of (2S) -isopropyl 2- (chlorine (naphthalen-2-yloxy) phosphorylamino) propanoate (0.54 ml, 270 pmol). The reaction mixture was then stirred at room temperature for 18 h. Methanol (2 ml) was added to stop the reaction. The mixture was purified by flash chromatography (silica gel, 1- 18% MeOH in DCM) and subjected to drying in vacuo to provide the title compound as a white solid (75 mg, 58%). LC-MS (MH) + = 596.1 Example 4 Preparation of isopropyl ester of (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4 - dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 - [((S) -1 -isopropoxycarbonyl - ethylamino) - (naphthalen -2 -yloxy) -phosphoryloxy] -4-methyl - tetrahydro-furan -2-ylmethoxy] - (naphthalen -2-yloxy) - phosphorylamino] –propionic
1-4 MW 916.81 C42H48F2N4O13P2
[00138] In the method described for the preparation of isopropyl ester of (S) -2 - [[(2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 - difluoro -3 -hydroxy -4 -methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen -2 -yloxy) -phosphorylamino] -propionic in Example 3 Step C, isopropyl acid ester (S) -2 - [[(2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 - [((S) -1 -isopropoxycarbonyl - ethylamino) - (naphthalen -2-yloxy) -phosphoryloxy] -4 -methyl - tetrahydro-furan -2 -ylmethoxy] - (naphthalen -2-yloxy) phosphorylamino] -propionic was obtained as the second product: white solid, 8 mg (4%). LC-MS (M + H) 1 = 917.2 Example 5 Preparation of isopropyl ester of (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3, 4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -4 -methyl -3-propionyloxy - tetrahydro-furan -2 -ylmethoxy] - (naphthalen -1 -yloxy) - phosphorylamino] –propionic
MW 653.58 C29H34F2N3O9P
[00139] To a solution of isopropyl ester of (S) -2 - [[((2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin- 1- il) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) -phosphorylamino] -propionic prepared in Example 2 (86 mg, 144 pmol) in THF (10 ml) were added propionyl chloride (66.6 mg, 720 pmol) and DMAP (87.9 mg, 720 pmol). The reaction mixture was stirred at room temperature for 5 h. The mixture was diluted with ethyl acetate, washed with water, brine. The organic layer was separated, dried over MgSO4, and concentrated. The residue was purified by flash chromatography (silica gel, 40 g, 0-15% MeOH in DCM) to provide the title compound as a white solid (45 mg, 48%). LC-MS (MH) + = 652.1 Example 6 Preparation of isopropyl ester of (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5 - (2,4-dioxide - 3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] - (naphthalen -2-yloxy) -phosphorylamino] - propionic chiral
1-6 MW 597.51 C26H30F2N3O9P
[00140] (S) —2— [[((2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) - 2 isopropyl ester , 4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] -propionic prepared in Example 3 (50 mg) was separated by means of SFC chromatography chiral to provide (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-l- isopropyl ester) il) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] - chiral propionic as a white solid (27 mg, 54 %) LC-MS (MH) + = 596.1 Example 7 Preparation of isopropyl ester of (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (2.4 - dioxo -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] - (naphthalen -2-yloxy) -phosphorylamino] propionic chiral
MW 597.51 C26H30F2N3O9P
[00141] Isopropyl ester of (S) -2 [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] - (naphthalen -2-yloxy) -phosphorylamino] - propionic prepared in Example 3 (50 mg) was separated by chiral SFC chromatography to provide (S) -2- [(R) - [(2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl isopropyl ester) ) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) - chiral phosphorylamino] -propionic as a white solid (12 mg, 24% ). LC-MS (MH) + = 596.1 Example 8 Preparation of isopropyl ester of (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (2,4-dioxide - 3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] - (naphthalen -1 -yloxy) -phosphorylamino] - propionic chiral
1-8 MW 597.51 C26H30F2N3O9P
[00142] Isopropyl ester of (S) -2 [[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] - (naphthalen -1-yloxy) -phosphorylamino] - propionic prepared in Example 2 (100 mg) was separated by chiral SEC chromatography to provide (S) -2- [(R) - [(2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl isopropyl ester) ) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic chiral as a white solid (24 mg, 24% ). LC-MS (MH) + = 596.1 Example 9 Preparation of isopropyl ester of (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5 - (2,4-dioxide - 3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] - (naphthalen -1 -yloxy) -phosphorylamino] - propionic chiral
1-9 MW 597.51 C26H30F2N3O9P
[00143] Isopropyl ester of (S) -2 [[[(2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] - (naphthalen -1-yloxy) -phosphorylamino] - propionic prepared in Example 2 (100 mg) was separated by chiral SFC chromatography to provide (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl isopropyl ester) ) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - chiral phosphorylamino] -propionic as a white solid (53 mg, 53% ) LC-MS (MH) + = 596.1 Example 10 Preparation of isopropyl ester of (S) -2 - {(S) - [(2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] -phenoxy -phosphorylamino} -propionic chiral
1-10 MW 547.45 C22H2 2 F2N3O9P
[00144] Isopropyl ester of (S) -2 {[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] -phenoxy -phosphorylamino} -propionic prepared in Example 1 (0.18 g) was separated by chiral SEC chromatography to provide isopropyl ester of (S) -2 - {(S) - [(2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4-difluoro - 3-hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] phenoxy -phosphorylamino} -chiral propionic as a white solid (60 mg, 33%). LC-MS (M + H) + = 548.0 Example 11 Preparation of isopropyl ester of (S) -2 - {(R) - [(2S, 3S, 4R, 5R) -5 - (2.4 - dioxo -3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl-tetrahydro-furan -2 -ylmethoxy] -phenoxy-phosphorylamino} -propionic chiral
1-11 MW 547.45 C22H28F2N3O9P
[00145] Isopropyl ester of (S) -2 {[((2S, 3S, 4R, 5R) -5 - (2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -yl) -2, 4 -difluoro -3 -hydroxy-4-methyl-tetrahydro-furan -2-ylmethoxy] -phenoxy -phosphorylamino} -propionic prepared in Example 1 (0.18 g) was separated by means of chiral SFC chromatography to provide isopropyl ester of (S) -2- {(R) - [(2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2, 4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] -phenoxy-phosphorylamino} - chiral propionic as a white solid (28 mg, 16%) LC-MS (M + H) + = 548.0 Example 12 Preparation of isopropyl ester of (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5 - (5-bromo -2,4-dioxide -3,4 -dihydro -2H - pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4 -methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic chiral
1-12 MW 676, 41 C26H39Br2NiO9P Step A.
[00146] To a solution of 5-bromo-1 - ((2R, 3R, 4S, 5S) - 3,5-difluoro-4-hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl) -1H-pyrimidine-2,4-dione chiral (50 mg, 0.14 mmol) prepared in Preparation 7 in THF (3 ml) under 0 ° C a THF solution (Aldrich, 1 M) of tert- butylmagnesium (0.35 ml, 0.35 mmol) drop by drop. The mixture was subjected to stirring at 0 ° C for 15 min, followed by the addition of THF solution (0.5 M) of (2S) -isopropyl 2- (chlorine (naphthalen-1-yloxy) phosphorylamino) propanoate prepared in Example 2 Step B (0.7 ml, 0.35 mmol). The reaction mixture was warmed to room temperature and subjected to stirring for 2 h. Methanol (2 ml) was added to stop the reaction. The mixture was purified by flash chromatography (5-10% MeOH in DCM) to provide isopropyl ester of (S) -2— [[((2S, 3S, 4R, 5R) -5- (5-bromo-2 , 4-dioxo-3,4,4-dihydro-2H-pyrimidin-1-yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) -phosphorylamino] - propionic as a white solid (50 mg, 52%). Step B.
[00147] Isopropyl ester of (S) -2 [[((2S, 3S, 4R, 5R) -5 - (5-bromine -2,4-dioxide -3,4-dihydro -2H -pyrimidin -1 -il ) -2,4 -difluoro -3 -hydroxy -4 -methyl - tetrahydro-furan -2 -ylmethoxy] - (naphthalen -1 -yloxy) phosphorylamino] -propionic (50 mg) was separated by chiral SFC chromatography to provide (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin- isopropyl ester) 1-yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) -phosphorylamino] -propionic chiral as a white solid (11 mg , 22%). LC-MS (M) + = 676.0 Example 13 Preparation of isopropyl ester of (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5 - (5-bromo -2, 4-dioxide -3,4-dihydro -2H - pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen -2-yloxy) - phosphorylamino] -chiral propionic
MW 676, 41 C26H39Br2N3O9P
[00148] (S) -2- [[[(2S, 3S, 4R, 5R) -5- (5-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-) isopropyl ester il) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] - propionic prepared in Example 16 (50 mg) was separated by chiral SEC chromatography to provide isopropyl ester of (S) -2 - [(S) - [(2S, 3S, 4R, 5R) -5 - (5 - bromine -2,4-dioxide -3,4 - dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4 -methyl-tetrahydro-furan-ylmethoxy] - (naphthalen -2 -yloxy) -phosphorylamino] -propionic chiral as a white solid (27 mg, 54%). LC-MS (M) + = 676.0 Example 14 Preparation of isopropyl ester of (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (5-bromo -2, 4-dioxide -3,4-dihydro -2H - pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen -1-yloxy) -
1-14 MW 676, 41 C26H39Br2N3O9P
[00149] During the separation of isopropyl ester from (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (5-bromine -2,4-dioxide - 3,4-dihydro -2H - pyrimidin -1 -yl) -2,4-difluoro -3 hydroxy -4-methyl-tetrahydro-furan-2-ylmethoxy] (naphthalen -1-yloxy) -phosphorylamino] -propionic (50 mg) by means of SFC chromatography chiral in Example 12 Step B, (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (5-bromine -2,4-dioxide -3,4 - isopropyl ester) chiral propionic dihydro -2H -pyrimidin -1 - yl) -2,4 -difluoro -3 -hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen -1-yloxy) -phosphorylamino] second product: white solid (8 mg, 16%). LC-MS (M) + = 676.0 Example 15 Preparation of isopropyl ester of (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (5-bromo -2, 4-dioxide -3,4-dihydro -2H - pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen -2-yloxy) - phosphorylamino] -chiral propionic
HO F 1-15 MW 676, 41 C26H39Br2N3OyP
[00150] During the separation of isopropyl ester from (S) -2 - [[((2S, 3S, 4R, 5R) -5 - (5-bromo -2,4-dioxide - 3,4-dihydro -2H - pyrimidin -1 -yl) -2,4-difluoro -3 - hydroxy -4-methyl-tetrahydro-furan -2-ylmethoxy] (naphthalen -2-yloxy) -phosphorylamino] -propionic prepared in Example 16 (50 mg) by chiral SFC chromatography means, isopropyl ester of (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5 - (5-bromine -2,4-dioxide -3) , 4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen -2-yloxy) phosphorylamino] -propionic chiral na form of the second product: white solid (16 mg, 32%). LC-MS (M) + = 675.9 Example 16 Preparation of isopropyl acid ester (S) -2 - [[(2S, 3S, 4R, 5R) -5 - (5-bromo -2,4-dioxide - 3,4-dihydro -2H -pyrimidin -1 -yl) -2,4 -difluoro -3 -hydroxy -4-methyl - tetrahydro-furan-2-ylmethoxy] - (naphthalen -2-yloxy) - phosphorylamino] -propionic chiral
MW 676, 41 C26H39Br2N3θ9P
[00151] To a solution of 5-bromine -1 - ((2R, 3R, 4S, 5S) -3,5-difluoro -4-hydroxy -5-hydroxymethyl -3-methyl - tetrahydro-furan-2-yl) -1H-pyrimidine -2,4-chiral dione (92 mg, 0.26 mmol) prepared in Preparation 7 in THF (3 ml) under 0 ° C a THF solution (Aldrich, 1 M) of tert- butylmagnesium (0.64 ml, 0.64 mmol) drop by drop. The mixture was stirred at 0 ° C for 15 min., Followed by the addition of a solution of THF (0.5 M) of (2S) -isopropyl 2- (chlorine (naphthalen-2-yloxy) phosphorylamino) propanoate prepared in Example 3 Step B (1.29 ml, 0.64 mmol). The reaction mixture was warmed to room temperature and subjected to stirring for 2 h. Methanol (2 ml) was added to stop the reaction. The mixture was purified by flash chromatography (5-10% MeOH in DCM) to provide the title compound as a white solid (56 mg, 32%). LC-MS (M) + = 676.0 Biological Examples HCV Replicon Assay
[00152] This assay measures the ability of the compounds of formula I to inhibit HCV RNA replication, and therefore their potential usefulness for the treatment of HCV infections. The assay uses a reporter as a single reading for the level of intracellular HCV replication RNA. The Renilla luciferase gene was introduced into the first reading frame of a NK5.1 genotype replication construct (N. Krieger et al., J. Virol. 2001 75 (10): 4614), immediately after the site sequence of internal ribosome entry (IRES), and fused to the neomycin phosphotransferase (NPTII) gene using a 2A auto-cleavage peptide from the foot and mouth of the disease virus (MD Ryan & J. Drew, EMBO 1994 13 (4): 928-933). After in vitro transcription, the RNA was electroporated in Huh7 human hepatoma cells, and G418 resistant colonies were isolated and expanded. The stably selected cell line 2209-23 contains replicating HCV subgenomic RNA, and the Renilla luciferase activity expressed through replication reflects its level of RNA in the cells. The assay was carried out in duplicate plates, one in opaque white and the other in transparent, in order to measure the antiviral activity and the cytotoxicity of a chemical compound in parallel, ensuring that the observed activity is not due to decreased or proliferating cell due to cell death.
[00153] HCV replication cells (2209 -23), which express the reporter Renilla luciferase, were cultured in Dulbecco's MEM (Invitrogen cat no. 10569-010) with 5% fetal bovine serum (FBS, Invitrogen cat No. 10082 147) and plated on a 96-well plate under 5000 cells per well, and incubated overnight. Twenty-four hours later, different dilutions of chemical compounds from the growth medium were added to the cells, which were then incubated under 37 ° C for three days. At the end of the incubation time, cells on white plates were harvested and luciferase activity was measured using the R. luciferase Assay assay system (Promega cat. E2820). All reagents described in the following paragraph were included in the manufacturer's kit, and the manufacturer's instructions for preparing the reagents were followed. The cells were washed once with 100 µl of phosphate buffered saline (pH 7.0) (PBS) per well and lysed with 20 µl lx buffer R.x. luciferase Assay before incubation at room temperature for 20 min . The plate was then inserted into the Centro LB 960 microplate luminometer (Berthold Technologies), and 100 pl of R. luciferase Assay buffer was injected into each well and the signal measured using a 2-second delay program, 2 seconds of measurement. The IC50, the drug concentration required to reduce the level of replication by 50% in relation to the control value of the untreated cell, can be calculated from the percentage reduction mark of luciferase activity vs. drug concentration as described above.
[00154] The reagent WST -1 from Roche Di agnostic (cat. No. 1644807) was used for the cytotoxicity assay. Ten micro liters (pL) of WST-1 reagent were added to each well of the transparent plates including wells containing media only as blanks. The cells were then incubated for 2 h at 37 ° C, and the OD value was measured using the MRX Revelation microtiter plate reader (Lab System) at 450 nm (reference filter under 650 nm). Again CC50, the drug concentration required to reduce cell proliferation by 50% in relation to the control value of untreated cells, can be calculated from the percentage reduction mark of the value of WST -1 vs. drug concentration as previously described.
[00155] Representative biological data is shown below in Table II.

[00156] It will be understood that references in this context to treatment extend to prophylaxis as well as treatment of existing conditions, and that treatment of animals includes treatment of humans as well as other mammals. In addition, the treatment of a Hepatitis C virus (HCV) infection, as used in this context, also includes the treatment or prophylaxis of a disease or condition associated with or mediated by the Hepatitis C virus infection ( HCV), or its clinical symptoms.
[00157] The aspects set out in the preceding description, or in the claims that follow, expressed in their specific forms or in terms of a means to carry out the exposed function, or a method or process for obtaining the exposed result, as appropriate , can, separately or in any combination of such aspects, can be used to carry out the invention in its various forms.
[00158] The preceding invention has been described in certain details by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one skilled in the art that changes and modifications can be practiced within the scope of the attached claims. For this reason, it should be understood that the foregoing description is intended to be illustrative and not restrictive. The scope of the invention should therefore be determined not with reference to the description presented, but should instead be determined with reference to the attached claims set out together with the full scope of equivalents to which such claims are entitled. The patents, published patent applications, and scientific literature referred to in this context establish their knowledge and are incorporated in this context by reference in their entirety to the same extent as if each were specifically and individually indicated to be incorporated by reference.

权利要求:
Claims (14)
[0001]
1 - Compound of Formula I
[0002]
2 - Compound according to claim 1, characterized by the fact that R4 is H.
[0003]
3 - Compound according to claim 2, characterized by the fact that R6 is H or Br.
[0004]
4 - Compound according to claim 3, characterized by the fact that R1 is naphthyl or phenyl.
[0005]
5 - Compound according to claim 4, characterized by the fact that R2a is H.
[0006]
6 - Compound according to claim 5, characterized by the fact that R2b is methyl.
[0007]
7 - Compound according to claim 6, characterized by the fact that R3 is isopropyl.
[0008]
8 - Compound according to claim 7, characterized by the fact that R & is H, C (= O) R1C or P (= 0) (OR1) (NR4R7).
[0009]
9 - Compound according to claim 7, characterized by the fact that R5 is C (= O) R1C and Rlc is ethyl.
[0010]
10 - Compound according to claim 7, characterized by the fact that R5 is P (= 0) (0R1) (NR4R7) and R1 is naphthyl.
[0011]
Compound according to claim 10, characterized by the fact that R4 is H and R7 is CH (CH3) C (= 0) OCH (CH3) 2.
[0012]
12 - Compound according to claim 1, characterized by the fact that it is selected from the group consisting of: isopropyl ester of (S) -2- {[((2S, 3S, 4R, 5R) -5- ( 2,4- Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] -phenoxy-phosphorylamino} - propionic ; (S) -2- [[((2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2,4- isopropyl ester difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic; (S) -2- [[((2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2,4- isopropyl ester difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) - phosphorylamino] -propionic; (S) -2 - [[((2S, 3S, 4R, 5R) -5- (2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2,4- isopropyl ester difluoro-3 - [((S) -1- isopropoxycarbonyl-ethylamino) - (naphthalen-2-yloxy) -phosphoryloxy] - 4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) - phosphorylamino ] -propionic; (S) -2 - [[((2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) -2, 4- isopropyl ester difluoro-4-methyl-3-propionyloxy-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic; (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-l-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) - phosphorylamino] -propionic; (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-l-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) - phosphorylamino] -propionic; (S) -2 - [(R) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-l-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic; (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-l-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) - phosphorylamino] -propionic; (S) -2- {(S) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] -phenoxy-phosphorylamino} - propionic; (S) -2 - {(R) - [(2S, 3S, 4R, 5R) -5- (2,4-Dioxo-3,4-dihydro-2H-pyrimidin-1-yl) - isopropyl ester - 2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] -phenoxy-phosphorylamino} - propionic; (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l isopropyl ester) -yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) -phosphorylamino] -propionic; (S) -2- [(S) - [(2S, 3S, 4R, 5R) -5- (5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l isopropyl ester) -yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] -propionic; (S) -2- [(R) - [(2S, 3S, 4R, 5R) -5- (5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1 isopropyl ester -yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-1-yloxy) -phosphorylamino] -propionic; (S) -2- [(R) - [(2S, 3S, 4R, 5R) -5- (5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1 isopropyl ester -yl) -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] -propionic; and (S) -2 - [[((2S, 3S, 4R, 5R) -5- (5-Bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl) isopropyl ester -2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy] - (naphthalen-2-yloxy) -phosphorylamino] -propionic.
[0013]
Compound according to any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, characterized in that it is for use in the treatment or prophylaxis of virus infection Hepatitis C (HCV).
[0014]
Pharmaceutical composition characterized by the fact that it comprises a compound as defined in any one of claims 1 to 12 and a therapeutically inert carrier.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP5982007B2|2016-08-31|2 ', 4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication

---

KR101687084B1|2016-12-15|4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication

---

KR102241198B1|2021-04-15|4'-fluoro-2'-methyl substituted nucleoside derivatives

---

TW201919649A|2019-06-01|4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication

---

US20210369755A1|2021-12-02|4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication

同族专利:

---

公开号 | 公开日

---

CA2856179A1|2013-06-27|

---

KR20140108290A|2014-09-05|

---

EA024297B1|2016-09-30|

---

RS56212B1|2017-11-30|

---

MX2014007023A|2014-09-12|

---

AU2012357940B2|2017-02-16|

---

CY1119056T1|2018-01-10|

---

AU2012357940A1|2014-05-29|

---

BR112014013661A8|2017-06-13|

---

PH12014501134B1|2014-07-28|

---

US20150004135A1|2015-01-01|

---

US9108999B2|2015-08-18|

---

HK1200836A1|2015-08-14|

---

ES2636448T3|2017-10-05|

---

PE20141423A1|2014-10-16|

---

BR112014013661A2|2017-06-13|

---

JP2015500852A|2015-01-08|

---

CR20140238A|2014-06-20|

---

EA201491179A1|2014-11-28|

---

ZA201404273B|2015-09-30|

---

CN104011061A|2014-08-27|

---

WO2013092481A1|2013-06-27|

---

PT2794629T|2017-07-20|

---

IL232505D0|2014-06-30|

---

SI2794629T1|2017-10-30|

---

DK2794629T3|2017-07-24|

---

NZ625342A|2016-07-29|

---

PH12014501134A1|2014-07-28|

---

SG11201403364PA|2014-07-30|

---

LT2794629T|2017-07-25|

---

EP2794629A1|2014-10-29|

---

KR101765997B1|2017-08-07|

---

HUE033727T2|2018-01-29|

---

JP5982007B2|2016-08-31|

---

CN104011061B|2017-06-13|

---

UA111761C2|2016-06-10|

---

CO6960551A2|2014-05-30|

---

PL2794629T3|2018-02-28|

---

MY171577A|2019-10-21|

---

HK1199036A1|2015-06-19|

---

MA35750B1|2014-12-01|

---

EP2794629B1|2017-05-24|

---

CL2014001562A1|2014-11-14|

---

IL232505A|2019-02-28|

---

CA2856179C|2017-02-28|

---

MX350809B|2017-09-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

AU498131B2|1974-02-26|1979-02-15|Ciba-Geigy Ag|Production of cephems by cyclization|

---

US4147864A|1975-02-20|1979-04-03|Ciba-Geigy Corporation|Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds|

---

US4322347A|1978-04-03|1982-03-30|Bristol-Myers Company|2-Carbamoyloxymethyl-penicillin derivatives|

---

WO1986006380A1|1985-04-30|1986-11-06|Takeda Chemical Industries, Ltd.|Antibacterial compounds, use and preparation thereof|

---

HU0004421A3|1996-04-23|2002-10-28|Vertex Pharmaceuticals Inc Cam|Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme|

---

US5807876A|1996-04-23|1998-09-15|Vertex Pharmaceuticals Incorporated|Inhibitors of IMPDH enzyme|

---

US6054472A|1996-04-23|2000-04-25|Vertex Pharmaceuticals, Incorporated|Inhibitors of IMPDH enzyme|

---

PL192280B1|1996-10-18|2006-09-29|Vertex Pharma|Inhibitors of serinic proteases in particular that of hepatitis c virus ns3|

---

GB9623908D0|1996-11-18|1997-01-08|Hoffmann La Roche|Amino acid derivatives|

---

US20030170891A1|2001-06-06|2003-09-11|Mcswiggen James A.|RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid |

---

JP4327910B2|1997-03-14|2009-09-09|バーテックスファーマシューティカルズインコーポレイテッド|Inhibitors of IMPDH enzyme|

---

US6010848A|1997-07-02|2000-01-04|Smithkline Beecham Corporation|Screening methods using an atpase protein from hepatitis C virus|

---

JP4452401B2|1997-08-11|2010-04-21|ベーリンガーインゲルハイム（カナダ）リミテッド|Hepatitis C virus inhibitory peptide analog|

---

DE69925918T2|1998-07-27|2006-05-11|Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.|DIKETIC ACID DERIVATIVES AS POLYMERASES INHIBITORS|

---

US6323180B1|1998-08-10|2001-11-27|Boehringer Ingelheim Ltd|Hepatitis C inhibitor tri-peptides|

---

ID27787A|1998-08-21|2001-04-26|Viro Pharma Inc|COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES|

---

AU751201B2|1998-09-04|2002-08-08|Viropharma Incorporated|Methods for treating or preventing viral infections and associated diseases|

---

EP1115286A4|1998-09-25|2003-07-23|Viropharma Inc|Methods for treating or preventing viral infections and associated diseases|

---

EP1178797B1|1999-03-19|2013-02-20|Vertex Pharmaceuticals Incorporated|Inhibitors of impdh enzyme|

---

AU1262001A|1999-11-04|2001-05-14|Biochem Pharma Inc.|Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues|

---

JP2004509066A|2000-05-10|2004-03-25|スミスクライン・ビーチャム・コーポレイション|New anti-infective drug|

---

US6448281B1|2000-07-06|2002-09-10|Boehringer Ingelheim Ltd.|Viral polymerase inhibitors|

---

SV2003000617A|2000-08-31|2003-01-13|Lilly Co Eli|INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M|

---

US20030175950A1|2001-05-29|2003-09-18|Mcswiggen James A.|RNA interference mediated inhibition of HIV gene expression using short interfering RNA|

---

CZ20033368A3|2001-06-11|2004-04-14|Shire Biochem Inc.|Thiophene derivatives as antiviral agents for flavivirus infection|

---

JP2005500287A|2001-06-11|2005-01-06|シャイアーバイオケムインコーポレイテッド|Compounds and methods for treatment or prevention of FLAVIRUS infections|

---

AR035543A1|2001-06-26|2004-06-16|Japan Tobacco Inc|THERAPEUTIC AGENT FOR HEPATITIS C THAT INCLUDES A CONDENSED RING COMPOUND, CONDENSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS, BENZIMIDAZOL, THIAZOL AND BIFENYL COMPOUNDS USED AS INTERMEDIARY COMPARTMENTS OF COMPARTMENTS|

---

CA2448737C|2001-07-20|2010-06-01|Boehringer Ingelheim Ltd.|Viral polymerase inhibitors|

---

EP2335700A1|2001-07-25|2011-06-22|Boehringer Ingelheim Ltd.|Hepatitis C virus polymerase inhibitors with a heterobicylic structure|

---

US20050009873A1|2001-11-02|2005-01-13|Gianpaolo Bravi|Acyl dihydro pyrrole derivatives as hcv inhibitors|

---

DE60221875T2|2001-11-02|2007-12-20|Glaxo Group Ltd., Greenford|4- HETEROARYL ACYL-PYRROLIDINE DERIVATIVES AS HCV INHIBITORS|

---

US20050043545A1|2001-11-02|2005-02-24|Gianpalol Bravi|4--heteroaryl acyl pyrrolidine derivatives as hcv inhibitors|

---

WO2004000858A2|2002-06-21|2003-12-31|Merck & Co., Inc.|Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase|

---

WO2004013298A2|2002-08-01|2004-02-12|Pharmasset Ltd.|2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections|

---

US20050020884A1|2003-02-25|2005-01-27|Hart Charles C.|Surgical access system|

---

WO2004096235A2|2003-04-25|2004-11-11|Gilead Sciences, Inc.|Anti-cancer phosphonate analogs|

---

EP1656093A2|2003-05-14|2006-05-17|Idenix Limited|Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses|

---

EP1644479A4|2003-06-16|2008-04-23|Mark W Grinstaff|Functional synthetic molecules and macromolecules for gene delivery|

---

GB0317009D0|2003-07-21|2003-08-27|Univ Cardiff|Chemical compounds|

---

AT461209T|2004-01-30|2010-04-15|Medivir Ab|HCV NS-3 SERINE PROTEASE INHIBITORS|

---

CA2590115A1|2004-12-10|2006-06-15|Emory University|2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation|

---

CA2618335C|2005-08-15|2015-03-31|F.Hoffmann-La Roche Ag|Antiviral phosphoramidates of 4'-substituted pronucleotides|

---

AU2007215114A1|2006-02-14|2007-08-23|Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.|Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection|

---

US8329159B2|2006-08-11|2012-12-11|Bristol-Myers Squibb Company|Hepatitis C virus inhibitors|

---

GB2442001A|2006-08-11|2008-03-26|Chembiotech|Nanoparticle - i-motif nucleic acid bioconjugates|

---

EP2102221B1|2006-12-11|2010-08-18|F. Hoffmann-La Roche AG|Process for preparation of 4'-azido cytidine derivatives|

---

US8071568B2|2007-01-05|2011-12-06|Merck Sharp & Dohme Corp.|Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection|

---

US7964580B2|2007-03-30|2011-06-21|Pharmasset, Inc.|Nucleoside phosphoramidate prodrugs|

---

GB0709791D0|2007-05-22|2007-06-27|Angeletti P Ist Richerche Bio|Antiviral agents|

---

US8173621B2|2008-06-11|2012-05-08|Gilead Pharmasset Llc|Nucleoside cyclicphosphates|

---

US9725479B2|2010-04-22|2017-08-08|Ionis Pharmaceuticals, Inc.|5′-end derivatives|

---

MX2013000656A|2010-07-19|2013-04-03|Gilead Sciences Inc|Methods for the preparation of diasteromerically pure phosphoramidate prodrugs.|

---

WO2013019874A1|2011-08-01|2013-02-07|Mbc Pharma, Inc.|Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates|WO2013039920A1|2011-09-12|2013-03-21|Idenix Pharmaceuticals, Inc.|Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections|

---

US9296778B2|2012-05-22|2016-03-29|Idenix Pharmaceuticals, Inc.|3′,5′-cyclic phosphate prodrugs for HCV infection|

---

WO2013177188A1|2012-05-22|2013-11-28|Idenix Pharmaceuticals, Inc.|3',5'-cyclic phosphoramidate prodrugs for hcv infection|

---

WO2013177219A1|2012-05-22|2013-11-28|Idenix Pharmaceuticals, Inc.|D-amino acid compounds for liver disease|

---

TW201408688A|2012-05-25|2014-03-01|Janssen R & D Ireland|Uracyl spirooxetane nucleosides|

---

EP2900682A1|2012-09-27|2015-08-05|IDENIX Pharmaceuticals, Inc.|Esters and malonates of sate prodrugs|

---

AP2015008384A0|2012-10-08|2015-04-30|Univ Montpellier Ct Nat De La Rech Scient|2'-Chloro nucleoside analogs for hcv infection|

---

US9211300B2|2012-12-19|2015-12-15|Idenix Pharmaceuticals Llc|4′-fluoro nucleosides for the treatment of HCV|

---

US9598457B2|2012-12-21|2017-03-21|Alios Biopharma, Inc.|Substituted nucleosides, nucleotides and analogs thereof|

---

SG11201504554UA|2012-12-21|2015-07-30|Alios Biopharma Inc|Substituted nucleosides, nucleotides and analogs thereof|

---

EP2970358B1|2013-03-04|2021-06-30|Idenix Pharmaceuticals LLC|3'-deoxy nucleosides for the treatment of hcv|

---

US9339541B2|2013-03-04|2016-05-17|Merck Sharp & Dohme Corp.|Thiophosphate nucleosides for the treatment of HCV|

---

CA2899763C|2013-03-08|2020-03-10|Nanjing Sanhome Pharmaceutical Co., Ltd.|Nucleoside phosphoramidate compound and use thereof|

---

EP2970357A1|2013-03-13|2016-01-20|IDENIX Pharmaceuticals, Inc.|Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv|

---

US9187515B2|2013-04-01|2015-11-17|Idenix Pharmaceuticals Llc|2′,4′-fluoro nucleosides for the treatment of HCV|

---

US20180200280A1|2013-05-16|2018-07-19|Riboscience Llc|4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication|

---

WO2014186637A1|2013-05-16|2014-11-20|Riboscience Llc|4'-fluor0-2'-methyl substituted nucleoside derivatives|

---

US10005779B2|2013-06-05|2018-06-26|Idenix Pharmaceuticals Llc|1′,4′-thio nucleosides for the treatment of HCV|

---

WO2015017713A1|2013-08-01|2015-02-05|Idenix Pharmaceuticals, Inc.|D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease|

---

EA201690526A1|2013-10-11|2017-02-28|Алиос Биофарма, Инк.|SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES|

---

WO2015061683A1|2013-10-25|2015-04-30|Idenix Pharmaceuticals, Inc.|D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv|

---

WO2015161137A1|2014-04-16|2015-10-22|Idenix Pharmaceuticals, Inc.|3'-substituted methyl or alkynyl nucleosides for the treatment of hcv|

---

EA201692535A1|2014-06-24|2017-05-31|Элиос Биофарма, Инк.|SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND THEIR ANALOGUES|

---

NZ727582A|2014-06-24|2018-06-29|Alios Biopharma Inc|Substituted nucleosides, nucleotides and analogs thereof|

---

WO2016078582A1|2014-11-20|2016-05-26|南京曼杰生物科技有限公司|Novel nucleoside phosphoramidate derivatives and applications thereof|

---

MA41441A|2014-12-19|2017-12-12|Alios Biopharma Inc|SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES OF THEM|

---

WO2017040766A1|2015-09-02|2017-03-09|Abbvie Inc.|Anti-viral tetrahydrofurane derivatives|

---

US10202412B2|2016-07-08|2019-02-12|Atea Pharmaceuticals, Inc.|β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections|

---

WO2018013937A1|2016-07-14|2018-01-18|Atea Pharmaceuticals, Inc.|Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection|

---

US10682369B2|2017-09-21|2020-06-16|Riboscience Llc|4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication|

---

SG11202008527WA|2018-03-07|2020-10-29|Univ Emory|4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto|

法律状态:
2017-12-19| B25A| Requested transfer of rights approved|Owner name: RIBOSCIENCE LLC (US) |

---

2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2019-04-24| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-06-18| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|

---

2020-02-11| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2020-06-02| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-10-27| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/12/2012, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161577707P| true| 2011-12-20|2011-12-20|

---

US61/577,707|2011-12-20|

---

PCT/EP2012/075779|WO2013092481A1|2011-12-20|2012-12-17|2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication|

---